NCT01974570View on ClinicalTrials.gov

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Prehypertension
Interventions
DIETARY_SUPPLEMENT

Marealis refined peptide concentrate

2 tablets, once per day before noon

DIETARY_SUPPLEMENT

Placebo

2 tablets, once per day before noon

Trial Locations (13)

60101

Biofortis Inc., Addison

N0N 1G0

Dr. William O'Mahony Medicine Professional Corporation, Corunna

L8J 0B6

Dr. Steven V. Zizzo Medicine Professional Corporation, Hamilton

N5W 6A2

Milestone Research, London

N5Y 5K7

Schacter Medicine Professional Corporation, London

N6A 5R8

KGK Synergize Inc., London

N6J 0A8

Dr. Dorli Herman, London

L3Y 5G8

SKDS Research Inc., Newmarket

N7T 4X3

Glencar Medical Inc., Sarnia

M9V 4B4

Dr. Anil Gupta Medicine Professional Corporation, Toronto

N4S 5P5

Devonshire Clinical Research, Woodstock

Unknown

A-Pharma, s.r.o, Prague

Analyze and Realize GmBH Professional Group, Berlin

Sponsors

Lead Sponsor

KGK Science Inc.
All Listed Sponsors
collaborator

Marealis AS

INDUSTRY

lead

KGK Science Inc.

INDUSTRY

NCT01974570 - Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects | Biotech Hunter | Biotech Hunter